ArticleIJTLD open2026
Quantifying emergent drug-resistant TB using laboratory data and record-linkage methods.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundClinicians, public health workers, and researchers must link multiple laboratory results to individual patient records to identify emerging drug-resistant TB.
objectiveDetermine the proportion of individuals with rifampicin-resistant TB (RR-TB) who developed fluoroquinolone resistance using different data matching methods.
designData from the National Health Laboratory Service (NHLS) from the Western Cape Province, South Africa (January 2008 to June 2015), were used to identify patients with RR-TB who developed fluoroquinolone resistance after initial susceptibility. We used four methods to link patient results: A) exact match on NHLS patient number; B) exact match on surname, first name, and date of birth; C) custom algorithm (Stellenbosch University) using approximate matches for patient-identifying variables; and D) custom iterative approximate linkage developed for this study. We manually reviewed matches identified by each method.
resultsWe identified 30,381 laboratory results showing rifampicin and fluoroquinolone susceptibility. Estimates of resistance development were 4% using methods A and B, and 8% using methods C and D. Across methods, 688 unique patients who developed fluoroquinolone resistance were identified, 598 of which were correct by manual review. Method D identified 587 (98%) of these correctly matched patients, the largest proportion across these methods.
conclusionCustomised approximate linkage approaches maximised correct patient matches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.